
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Research Service, Stratton Veterans Affairs Medical Center, 2 Ordway Research Institute, 3 Center for Cardiovascular Sciences, Albany Medical College, and 4 Wadsworth Center, New York State Department of Health, Albany, New York
Requests for reprints: Faith B. Davis, Center for Medical Science, Ordway Research Institute, 150 New Scotland Avenue, Albany, NY 12208. Phone: 518-641-6465; Fax: 518-262-5008. E-mail: fdavis{at}ordwayresearch.org
Resveratrol, a naturally occurring stilbene with antitumor properties, caused mitogen-activated protein kinase [MAPK, extracellular signal-regulated kinase 1/2 (ERK1/2)] activation, nuclear translocation of Ser15-phosphorylated p53, and p53-dependent apoptosis in hormone-insensitive DU145 prostate cancer cells. Exposure of these cells to epidermal growth factor (EGF) for up to 4 hours resulted in brief activation of MAPK followed by inhibition of resveratrol-induced signal transduction, p53 phosphorylation, and apoptosis. Resveratrol stimulated c-fos and c-jun expression in DU145 cells, an effect also suppressed by EGF. An inhibitor of protein kinase C (PKC)-
, -ß, and -
(CGP41251) enhanced Ser15 phosphorylation of p53 by resveratrol in the absence of EGF and blocked EGF inhibition of the resveratrol effect. EGF caused PKC-
/ß phosphorylation in DU145 cells, an effect reversed by CGP41251. Activation of PKC by phorbol ester (phorbol 12-myristate 13-acetate) enhanced EGF action on ERK1/2 phosphorylation without significantly altering p53 phosphorylation by resveratrol. DU145 cells transfected with a dominant-negative PKC-
construct showed resveratrol-induced ERK1/2 phosphorylation and Ser15 phosphorylation of p53 but were unresponsive to EGF. Thus, resveratrol and EGF activate MAPK by discrete mechanisms in DU145 cells. The stilbene promoted p53-dependent apoptosis, whereas EGF opposed induction of apoptosis by resveratrol via a PKC-
-mediated mechanism. Resveratrol also induced p53 phosphorylation in LNCaP prostate cancer cells, an effect also inhibited by EGF. Inhibition of PKC activation in LNCaP cells, however, resulted in a reduction, rather than increase, in p53 activation and apoptosis, suggesting that resveratrol-induced apoptosis in these two cell lines occurs through different PKC-mediated and MAPK-dependent pathways.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 3/17/04; revised 7/26/04; accepted 8/27/04.
This article has been cited by other articles:
![]() |
H.-Y. Lin, H.-Y. Tang, T. Keating, Y.-H. Wu, A. Shih, D. Hammond, M. Sun, A. Hercbergs, F. B. Davis, and P. J. Davis Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated Carcinogenesis, January 1, 2008; 29(1): 62 - 69. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-H. Kweon, V. M. Adhami, J.-S. Lee, and H. Mukhtar Constitutive Overexpression of Nrf2-dependent Heme Oxygenase-1 in A549 Cells Contributes to Resistance to Apoptosis Induced by Epigallocatechin 3-Gallate J. Biol. Chem., November 3, 2006; 281(44): 33761 - 33772. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-Y. Tang, A. Shih, H. J. Cao, F. B. Davis, P. J. Davis, and H.-Y. Lin Resveratrol-induced cyclooxygenase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol. Cancer Ther., August 1, 2006; 5(8): 2034 - 2042. [Abstract] [Full Text] [PDF] |
||||
![]() |
H.-Y. Lin, L. Lansing, J.-M. Merillon, F. B. Davis, H.-Y. Tang, A. Shih, X. Vitrac, S. Krisa, T. Keating, H. J. Cao, et al. Integrin {alpha}V{beta}3 contains a receptor site for resveratrol FASEB J, August 1, 2006; 20(10): 1742 - 1744. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Kotha, M. Sekharam, L. Cilenti, K. Siddiquee, A. Khaled, A. S. Zervos, B. Carter, J. Turkson, and R. Jove Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther., March 1, 2006; 5(3): 621 - 629. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |